Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

Gutzmer, Ralf; Stroyakovskiy, Daniil; Gogas, Helen; Robert, Caroline; Lewis, Karl; Protsenko, Svetlana; Pereira, Rodrigo P.; Eigentler, Thomas; Rutkowski, Piotr; Demidov, Lev; Manikhas, Georgy Moiseevich; Yan, Yibing; Huang, Kuan-Chieh; Uyei, Anne; McNally, Virginia; McArthur, Grant A.; Ascierto, Paolo A.

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

Author:

Gutzmer, Ralf; Stroyakovskiy, Daniil; Gogas, Helen; Robert, Caroline; Lewis, Karl; Protsenko, Svetlana; Pereira, Rodrigo P.; Eigentler, Thomas; Rutkowski, Piotr; Demidov, Lev; Manikhas, Georgy Moiseevich; Yan, Yibing; Huang, Kuan-Chieh; Uyei, Anne; McNally, Virginia; McArthur, Grant A.; Ascierto, Paolo A.

Tübinger Autor(en):

Eigentler, Thomas

Published in:

Lancet (2020), Bd. 395, H. 10240, S. 1835-1844

Verlagsangabe:

Elsevier Science Inc

Language:

English

Full text:

https://doi.org/10.1016/S0140-6736(20)30934-X

ISSN:

1474-547X